Draft:Saadi Corporation Limited
 | |
| Company type | Private |
|---|---|
| Industry | Research, Healthcare |
| Founded | 2019 |
| Headquarters | Lahore, Punjab, Pakistan, 54790. |
Key people |
|
Number of employees | ≈ 9 (August 2024) |
| Website | saadicorp |
Saadi Corporation Limited (commonly known as SaadiCorp) is a research institute based in Lahore, Pakistan, that specialises in leveraging artificial intelligence (AI) to drive advancements in healthcare research. The company is primarily dedicated to developing innovative solutions for personalized medicine, with a key focus on the early diagnosis, treatment, and management of thyroid cancer. SaadiCorp’s mission is to integrate cutting-edge technology with medical expertise to improve patient outcomes and contribute to the global healthcare landscape.
Since its inception in 2019, SaadiCorp has made significant contributions to the medical field through a variety of initiatives. The company collaborates with leading hospitals and research centre to sponsor clinical trials, support research fellowships, and develop AI-powered systems aimed at improving early detection methods, diagnostic accuracy, and personalized treatment plans for thyroid cancer.
SaadiCorp's research efforts are driven by its commitment to addressing the challenges of thyroid cancer, which remains one of the most prevalent endocrine malignancies. The company has invested over PKR 9.5 million in thyroid cancer research, funded over 10 clinical trials, and supported 15 research fellowships to explore novel therapies and methods for early detection.
This research is conducted in close collaboration with the Cancer Care Hospital & Research Centre, and aims to reduce the high rate of underdiagnosed cases in Pakistan.
Through its AI-driven research, SaadiCorp is working on predictive models and genomic analysis tools that assist in identifying high-risk patients early on. By combining artificial intelligence with traditional medical practices, the company seeks to revolutionize the way healthcare providers approach thyroid cancer diagnosis and treatment.
History
[edit]SaadiCorp was established in 2019 by Muhammad Salman Saadi. In late 2023, Naveed Khalid acquired a 75% ownership stake in the company and took over as Chairman. This acquisition marked the company's expansion into AI and healthcare research, especially in the field of thyroid cancer.
Healthcare Research
[edit]SaadiCorp’s core research efforts are centered around thyroid cancer. The company has collaborated with medical institutions such as the Cancer Care Hospital & Research Centre to improve early diagnosis and develop novel treatment methods. The company has invested over PKR 9.5 million into research projects aimed at advancing early detection techniques, predictive models, and AI-driven therapies for thyroid cancer.
Ownership and Leadership
[edit]As of 2023, Naveed Khalid holds a 99% ownership stake in SaadiCorp and serves as the CEO of the company. The original founder, Muhammad Salman Saadi, previously held the role of CEO but stepped down following the change in ownership. The company's headquarters are located in Lahore, Punjab, Pakistan.
References
[edit]External Links
[edit]Official Website: www.saadicorp.ltd